CaRE Program & Renal Physiology Laboratory
Since July 2014, the Divisions of Nephrology, Cardiology and Endocrinology & Metabolism at the University Health Network have collaborated to form a combined Cardiology-Renal-Endocrine (CaRE) clinical program, serving patients with diabetes and cardiovascular and/or renal complications.
About Us
Dr. Cherney is the director of the Renal Physiology Laboratory. With a specific interest in the relationship between diabetes and kidney and heart disease, Dr. Cherney’s research focuses on the physiological factors that lead to kidney disease in patients with diabetes. He leads a number of large clinical trials that look at the different causes of kidney disease, particularly diabetes.
Leadership
-
Dr. David CherneyProfessor of Medicine - University of TorontoNephrologist - UHNSenior Scientist - Toronto General Hospital Research Institute
Awards
-
2019
The American Society of Nephrology Distinguished Researcher Award (USA)
Awarded by the American Society of Nephrology.
-
2019
Diabetes Canada/Canadian Institutes of Health Research (CIHR)
An Institute of Nutrition Diabetes and Metabolism Young Scientist Award.
-
2017
William Goldie Prize and Travel Award for Research, Department of Medicine, University of Toronto (Canada)
The William Goldie Prize and Travel Award recognizes meritorious members of the Department of Medicine.
-
2013
Excellence in Clinical Teaching Award, Faculty of Medicine, Wightman-Berris Academy (Canada)
The Teaching Performance Awards recognize teachers whose outstanding skills have been identified by their students
-
2007-08
New Faculty Excellence in Teaching, Wightman-Berris Academy (Canada)
The Teaching Performance Awards recognize teachers whose outstanding skills have been identified by their students.
-
2006
First Prize, Renal Trainee Clinical Research Project
A University of Toronto Renal Trainee Research Day award.
Clinical Trials
-
SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetes (SMART)
Quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem enim ad minima veniam, quis nostrum exercitationem.
-
Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD
Quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem enim ad minima veniam, quis nostrum exercitationem.
Publications
-
2023
Cardiorenal Outcomes, Kidney Function, and Other Safety Outcomes with Ertugliflozin in Older Adults with Type 2 Diabetes (VERTIS CV): Secondary Analyses From a Randomised, Double-Blind Trial -
2022
Impact of Diabetes on the Effects of Sodium Glucose Co-transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-analysis of Large Placebo-Controlled Trials -
2022
Empagliflozin in Patients with Chronic Kidney Disease